Molecular targeting radiotherapy with Cyclo-RGDfK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice

Journal of Biomedical Nanotechnology

Volumn 10, Issue 3, 2014, Pages 393-404

  Vilchis Juárez, Andrea ^a,b   Ferro Flores, Guillermina ^a   Santos Cuevas, Clara ^a   Morales Avila, Enrique ^b   Ocampo García, Blanca ^a   Díaz Nieto, Lorenza ^c   Luna Gutiérrez, Myrna ^a,b   Jiménez Mancilla, Nallely ^a,b   Pedraza López, Martha ^c   Gómez Oliván, Leobardo ^b  

^a INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Lutetium 177; Radiolabeled Gold Nanospheres; RGD Peptides; Targeted Radiotherapy

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CHEMORADIOTHERAPY; GOLD; LUTETIUM; MALE; METAL NANOPARTICLES; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NANOCONJUGATES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; RADIOISOTOPES; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893773380     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1721     Document Type: Article

References (31)

1. D. L. Morse and R. J. Gillies, Molecular imaging and targeted therapies. Biochem. Pharmacol. 80, 731 (2010).
2. M. Patel, M. A. Vogelbaum, G. H. Barnett, R. Jalali, and M. S. Ahluwalia, Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert. Opin. Investig. Drugs 21, 1247 (2012).
3. 177Lu-DOTATATE: Which is a better therapy option?. Eur. J. Nucl. Med. Mol. Imaging 38, 1788 (2011).
4. 3-octreotate. J. Nucl. Med. 46, 83S (2005).
5. 177Lu-DOTATATE: The IEO phase I-II study. Eur. J. Nucl. Med. Mol. Imaging 38, 2125 (2011).
6. 188Re-pharmaceuticals. Adv. Drug Deliv. Rev. 60, 1389 (2008).
7. G. Tabatabai, J. C. Tonn, R. Stupp, and M. Weller, The role of integrins in glioma biology and anti-glioma therapies. Curr. Pharm. Des. 17, 2402 (2011).
8. S. Liu, Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol. Pharmaceutics 3, 472 (2006).
9. S Liu, Radiolabeled cyclic RGD peptides as integrin β3-targeted radiotracers: Maximizing binding affinity via bivalency. Bioconjugate Chem. 20, 2199 (2009).
10. R. Haubner and C. Decristoforo, Radiolabeled RGD peptides and peptidomimetics for tumor targeting. Front. Biosci. 14, 872 (2009).
11. P. M. Mitrasinovic, Advances in β(3) integrin targeting cancer therapy and imaging with radiolabeled RGD peptides. Curr. Radiopharm. 2, 214 (2009).
12. X. Montet, M. Funovics, K, Montet-Abou, R. Weissleder, and J. Lee, Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 49, 6087 (2006).
13. C. Huang, Q. Bao, D. Hunting, Y. Zheng, and L. Sanchez, Conformation-dependent DNA damage induced by gold nanoparticles. J. Biomed. Nanotechnol. 9, 856 (2013).
14. J. H. An, B. K. Oh, and J. W. Choi, Detection of tyrosine hydroxylase in dopaminergic neuron cell using gold nanoparticles-based barcode DNA. J. Biomed. Nanotechnol. 9, 639 (2013).
15. Y. Qu, Y. Huang, and X. Lü. Proteomic analysis of molecular biocompatibility of gold nanoparticles to human dermal fibroblastsfetal. J. Biomed. Nanotechnol. 9, 40 (2013).
16. 99mTc-labeled Gold Nanoparticles Conjugated to c[RGDfK(C)] for Molecular Imaging of Tumor α(v)β(3) expression. Bioconjugate Chem. 22, 913 (2011).
17. 177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing α(v)β(3) integrins. J. Labelled Comp. Radiopharm. 50, 140 (2012).
18. E. Morales-Avila, G. Ferro-Flores, B. E. Ocampo-García, and L. Gómez-Oliván, Engineered Multifunctional RGD-Gold Nanoparticles for the Detection of Tumour specific α(v) β(3) Expression: Chemical Characterisation and Ecotoxicological Risk Assessment. J. Biomed. Nanotechnol. 8, 991 (2012).
19. 99mTc-Radiopharmaceuticals Based on Gold Nanoparticles. Nucl. Med. Comm. 32, 1095 (2011).
20. 177Lu-DOTATATE in athymic mice with induced pancreatic malignant tumours: Preclinical studies. Radiat. Eff. Defects Solids 162, 791 (2007).
21. 177Lu radionuclides. Cancer Biother. Radiopharm. 20, 436 (2005).
22. 177Lu-DOTATATE: The role of associated risk factors. Eur. J. Nucl. Med. Mol. Imaging 35, 1847 (2008).
23. 2can modify the conjugation and stability of gold nanoparticles and their affinity for beta-amyloid fibrils. Bioconjugate Chem. 19, 1154 (2008).
24. T. Poethko, G. Thumshirn, U. Hersel, F. Rau, R. Haubner, M. Schwaiger, H. Kessler, and H. J. Wester, Improved tumor uptake, tumor retention and tumor/background ratios of pegylated RGD multimers. J. Nucl. Med. 44, 46P (2003).
25. E. Vegt, M. Jong, J. Wetzels, R. Masereeuw, M. Melis, W. J. Oyen, M. Gotthardt, and O. C. Boerman, Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med. 51, 1049 (2010).
26. C. F. Montenegro, C. L. Salla-Pontes, J. U. Ribeiro, A. Z. Machado, R. F. Ramos, C. C. Figueiredo, V. Morandi, and H. S. Selistre-de-Araujo, Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells. Biochimie 94, 1812 (2012).
27. M. Franckena, R. De Wit, A. C. Ansink, A. Notenboom, R. A. Canters, D. Fatehi, G. C. Van Rhoon, and J. Van Der Zee, Weekly systemic cisplatin plus locoregional hyperthermia: An effective treatment for patients with previously irradiated recurrent cervical carcinoma in a previously irradiated area. Int. J. Hyperthermia 23, 443 (2007).
28. M. Franckena, L. C. Lutgens, P. C. Koper, C. E. Kleynen, E. M. van der Steen-Banasik, J. J. Jobsen, J. W. Leer, C. L. Creutzberg, M. F. Dielwart, Y. van Norden, R. A. Canters, G. C. van Rhoon, and J. van der Zee, Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: Results in 378 patients. Int. J. Radiat. Oncol. Biol. Phys. 73, 242 (2009).
29. X. Huang, W. Qian, I. H. El-Sayed, and M. A. El-Sayed, The potential use of the enhanced nonlinear properties of gold nanospheres in photothermal cancer therapy. Lasers Surg. Med. 39, 747 (2007).
30. H. Mendoza-Nava, G. Ferro-Flores, B. Ocampo-García, J. Serment-Guerrero, C. Santos-Cuevas, N. Jiménez-Mancilla, M. Luna-Gutiérrez, and M. A. Camacho-López, Laser heating of gold nanospheres functionalized with octreotide: In vitro effect on HeLa cell viability. Photomed. Laser Surg. 31, 17 (2013).
31. N. Chanda, V. Kattumuri, R. Shukla, A. Zambre, K. Katti, A. Upendran, R. R. Kulkarni, P. Kan, G. M. Fent, S. W. Casteel, C. J. Smith, E. Boote, J. D. Robertson, C. Cutler, J. R. Lever, K. V. Katti, and R. Kannan, Bombesin functionalized gold nanoparticles show In vitro and In vivo cancer receptor specificity. Proc. Natl. Acad. Sci. USA 107, 8760 (2010).